Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.